- Active not recruitingPHASE1
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
This study is looking into new ways to treat advanced cancers that have a specific genetic change called KRAS p.G12C. It's testing a drug called sotorasib, either by itself or with other treatments, to see how safe and effective they are for adults.
For: Advanced Solid Tumors · Kirsten Rat Sarcoma (KRAS) pG12C MutationUnited States · Australia · Austria - RecruitingPHASE3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
This study is for people with advanced bowel cancer that has spread and has a specific gene change called KRAS p.G12C. It compares a new combination of treatments to standard treatment to see if it can better stop the cancer from growing.
For: Metastatic Colorectal CancerUnited States · Argentina · Australia - RecruitingPHASE1
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
This study is looking at a new medicine, AMG 410, for cancers with a specific change called KRAS. We want to see how safe it is, how it works in the body, and if it helps shrink tumors, both on its own and with other medicines.
For: KRAS Altered Advanced or Metastatic Solid TumorsUnited States · Australia · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase II study evaluating Holmium-166 TARE followed by maIntenance Therapy in liver limited unresectable colorectal cancer patients after first-lIne chemotherapy and target agents: The HAITI study.
This study looks at a new way to treat bowel cancer that has spread only to the liver and can't be removed with surgery. It combines a special radiation treatment with regular cancer medicines to see if it can stop the cancer from growing for longer. It's for adults who have already had some chemotherapy.
For: Liver limited unresectable colorectal cancerItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
PRODIGE 54 SAMCO : MULTICENTER RANDOMIZED PHASE II STUDY COMPARING THE EFFECTIVENESS AND TOLERANCE OF AVELUMAB VERSUS STANDARD 2nd LINE TREATMENT CHEMOTHERAPY IN PATIENTS WITH COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY (MSI)
This study compares a new drug, avelumab, with standard chemotherapy for advanced bowel cancer that has spread and has specific genetic changes (microsatellite instability). We want to see if avelumab can stop the cancer from growing for longer.
For: COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITYFrance